Company intelligence / Profile preview

Resistys

Old Saybrook, Connecticut, United States

Ownership: Private
Development stage: Other

Overview

Resistys is a preclinical-stage biotechnology company focused on developing novel small molecule therapeutics to overcome acquired resistance in cancer. The company specifically targets resistance mutations that arise following treatment with standard-of-care targeted therapies, such as third-generation EGFR inhibitors. Its lead research efforts are directed toward addressing the C797S mutation in non-small cell lung cancer (NSCLC), a common cause of treatment failure. Led by experienced pharmaceutical executives, Resistys aims to extend the lives of patients by restoring the efficacy of precision medicine.

Therapeutic areas: Oncology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Resistys.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Resistys.

Explore the full profile